Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients

Journal of Gastrointestinal Cancer

Volumn 47, Issue 1, 2016, Pages 15-19

  Oziel Taieb, Sandrine ^a   Faure, Marjorie ^a   Gilabert, Marine ^a   Autret, Aurélie ^a   Turrini, Olivier ^a   Moureau Zabotto, Laurence ^a   Giovannini, Marc ^a   Rousseau, Frederique ^a   Raoul, Jean Luc ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Elderly; Gemcitabine; Pancreatic adenocarcinoma; Resection; Systemic chemotherapy

Indexed keywords

GEMCITABINE;

ADJUVANT CHEMOTHERAPY; AGED; ARTICLE; CANCER SURGERY; CHEMORADIOTHERAPY; CHOLEDOCOJEJUNOSTOMY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROJEJUNOSTOMY; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TREATMENT OUTCOME; ADENOCARCINOMA; CANCER STAGING; CARCINOMA, PANCREATIC DUCTAL; FOLLOW UP; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; PANCREATIC NEOPLASMS; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84958062226     PISSN: 19416628     EISSN: 19416636     Source Type: Journal    
DOI: 10.1007/s12029-015-9774-4     Document Type: Article

References (24)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin. 2010;60:277–300.
2. Hill C, Doyon F. The frequency of cancer in France in year 2002, and trends since 1968. Bull Cancer. 2006;93:7–11.
3. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T. Cancer incidence and incidence rates in Japan in 2003: based on data from 13 population-based cancer registries in the monitoring of cancer incidence in Japan project. Jpn J Clin Oncol. 2009;39:850–8.
4. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5 – a population based study. Lancet Oncol. 2014;15:23–34.
5. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362:1605–17.
6. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.
7. Von Hoff D, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-Paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.
8. Von Hoff DD, Ramanathan RK, Borad MJ, et al. Gemcitabine plus nab-Paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548–54.
9. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6:699–708.
10. Baine M, Sahak F, Lin C, Chakraborty S, Lyden E, Batra SK. Marital status and survival in pancreaticn cancer patients: a SEER, based analysis. PLoS One. 2011;6, e21052.
11. Raoul JL, Turrini O, Goncalves A, Gilabert M, Giovannini M, Rousseau F. Why is pancreatic cancer difficult to treat in the elderly? Aging Health. 2012;8:301–8.
12. Hartwig W, Werner J, Jäger D, Debus J, Büchler MW. Improvement of surgical results for pancreatic cancer. Lancet Oncol. 2013;14:e476–85.
13. Fong Y, Blumgart L, Fortner JG, Brennan MF. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg. 1995;222:426–37.
14. Lahat G, Sever R, Lubezky N, et al. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. World J Surg Oncol. 2011;9:1–8.
15. Hatzaras I, Schmidt C, Klemanski D, et al. Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy. J Am Coll Surg. 2011;212:373–7.
16. Turrini O, Paye F, Bachellier P, Sauvanet A, Sa Cunha A, Le Treut YP, et al. Pancreatectomy for adenocarcinoma ijn elderly patients: postoperative outcomes and long term results. A study of the French Surgical Association. Eur J Surg Oncol. 2013;39:171–8.
17. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long term outcomes among patients with resected pancreatic cancer. The CONKO-001 randomized trial. JAMA. 2013;310:1473–81.
18. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304:1073–81.
19. Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R, et al. A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol. 2002;13:1185–91.
20. Dahan L, Bonnetain F, Ychou M, Mitry E, Gasmi M, Raoul JL, et al. Combination 5-fluorouraci, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut. 2010;59:1527–34.
21. Hentic O, Dreyer C, Rebours V, Zappa M, Levy P, Raymond E, et al. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol. 2011;17:3497–502.
22. Yukisawa S, Ishii H, Matsuyama M, Kuraoka K, Takano K, Kamei A, et al. Outcomes and tolerability of systemic chemotherapy for pancreatic or biliary cancer patients aged 75 years or older. Jpn J Clin Oncol. 2011;41:76–80.
23. Loehrer Sr PJ, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol. 2011;29:4105–12.
24. Chauffert B, Mornex F, Bonnetain F, Rougier P, Mariette C, Bouche O, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.